Skyhawk Therapeutics

Skyhawk Therapeutics is a biotechnology company specializing in the development of RNA-targeting small molecule therapies to treat a range of diseases, including cancer, neurodegenerative disorders, and rare genetic conditions. The company leverages its proprietary SkySTAR platform to design and optimize molecules that modulate RNA splicing, addressing previously undruggable targets. Founded in 2016, Skyhawk has established strategic collaborations with major pharmaceutical companies like Biogen, Takeda, and Merck, which contribute to its revenue through partnerships and licensing agreements. Candidates should note the company's innovative approach to drug discovery and its focus on advancing precision medicine.

Recent Posts by Skyhawk Therapeutics

1-2 of 2